2010
DOI: 10.1016/j.brainres.2010.05.084
|View full text |Cite
|
Sign up to set email alerts
|

Abstract: We have previously used fluorodeoxyglucose (FDG) autoradiography to detect the pattern of metabolic declines in two different transgenic mouse models of fibrillar beta-amyloid pathology in Alzheimer's disease (AD), including the PDAPP mouse, which overexpresses a mutant form of human APP, and the PSAPP mouse, which overexpresses mutant forms of the human APP and PS1 genes. In this study, we used the same approach to study a triple-transgenic (3xTG) model of AD, which overexpresses human APP, PS1 and tau mutati… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
2
1

Citation Types

9
64
1
1

Year Published

2013
2013
2023
2023

Publication Types

Select...
5
1

Relationship

0
6

Authors

Journals

citations
Cited by 91 publications
(75 citation statements)
references
References 30 publications
9
64
1
1
Order By: Relevance
“…The prodromal stage encompasses the presymptomatic and mild cognitive impairment stages of AD. White line = progression of cognitive decline through the 5 stages of AD [11][12][13][14][15][16][17]. FDG-PET = fluoro-2-deoxyglucose positron emission tomography; MRI, magnetic resonance imaging adenosine triphosphate (ATP) production [9].…”
Section: Current Strategies Targeting Mitochondria and Bioenergetics mentioning
confidence: 99%
See 4 more Smart Citations
“…The prodromal stage encompasses the presymptomatic and mild cognitive impairment stages of AD. White line = progression of cognitive decline through the 5 stages of AD [11][12][13][14][15][16][17]. FDG-PET = fluoro-2-deoxyglucose positron emission tomography; MRI, magnetic resonance imaging adenosine triphosphate (ATP) production [9].…”
Section: Current Strategies Targeting Mitochondria and Bioenergetics mentioning
confidence: 99%
“…Multiple experimental paradigms, ranging from in vitro cell model systems and genomic analyses in animal models to postmortem autopsy of human brain and human brain imaging indicate deficits in mitochondrial function are consistent antecedents to AD development [11][12][13]24]. A decline in mitochondrial function can occur decades prior to clinical diagnosis of AD and thus may serve as a biomarker of AD risk, as well as a therapeutic target [12,24,32,67].…”
Section: Mitochondrial Bioenergetics As a Therapeutic Targetmentioning
confidence: 99%
See 3 more Smart Citations